Clinical Trials Report for January 2015 | Aplastic Anemia and MDS International Foundation

Clinical Trials Report for January 2015

We have highlighted some clinical trials currently recruiting patients. Each has a specific purpose related to aplastic anemia, MDS, or PNH. Should you consider a clinical trial?  Ask your doctor or contact the study coordinators for further information. Learn more in the Clinical Trials section.

If you only want to see studies that are currently recruiting patients, select that option from the “recruitment” line at the beginning of the advanced search. To locate a clinical trial in your state, use the “advanced search” feature. Under locations, select your state(s) and your country.

Search for aplastic anemia studies actively recruiting patients. The following are a sample of the 72 open studies recruiting aplastic anemia patients in the United States.

Title/Link to more information

Study Purpose

Study Coordinator

Fertility Preservation in Women Who Will Have Gonadotoxic Therapy or Hematopoetic Stem Cell Transplantation, and in Women With Sickle Cell Disease Some treatments for cancer or other diseases can lead to infertility in women. These treatments include chemotherapy, some stem cell transplants, and pelvic radiotherapy. They are called gonadotoxic therapies. Women can now have their eggs frozen before they have these treatments. This may allow them to get pregnant later. Researchers want to learn more about this technology and processes.
This study if for women at least 18 years old who are past puberty and before menopause. They must be scheduled to have gonadotoxic therapies.
National Institutes of Health Clinical Center

Contact: Christine L Atallah, R.N.   
(301) 435-7926 christine.atallah@nih.gov
   
Please refer to this study by its ClinicalTrials.gov identifier: NCT02225145

Seach for myelodysplastic syndromes studies actively recruiting patients. The following MDS studies are a sample of the 321 studies recruiting MDS patients in the United States.

Title/Link to more information

Study Purpose

Study Coordinator

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

The goal of this clinical research study is to compare how 2 different drugs, decitabine and azacitidine, when given on a shorter than standard dosing schedule, may help to control MDS. The safety of each study drug given on these schedules will also be studied. This study is being conducted at MD Anderson Cancer Center
Contact: Elias Jabbour, MD, 713-792-4764
Please refer to this study by its ClinicalTrials.gov identifier: NCT02269280




A Dose Escalation and Cohort Expansion Study of TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome TEN-010 is a small molecule, bromodomain and extra-terminal domain (BET) bromodomain inhibitor. This study is designed to characterize the safety, tolerability, and pharmacokinetics of TEN-010 in patients with relapsed/refractory acute myeloid leukemia (RR-AML) and hypomethylating agent (HMA)-refractory myelodysplastic syndrome (MDS). In addition, this trial will assess response to treatment using International Working Group (IWG) response criteria. This study is being conducted at
Weill Cornell Medical College in New York Center
Contact: Tania Curcio    212-746-2571
tjc9003@med.cornell.edu  
Please refer to this study by its ClinicalTrials.gov identifier: NCT02308761
Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes

This study is being performed to assess the safety, tolerability, and preliminary clinical effects of BVD-523 given orally, twice daily for 21-day cycles, in patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS). This study is being conducted at he University of Texas MD Anderson Cancer Center
Contact: Thomas Medina, RN, 713-745-1847 TEMedina@mdanderson.org 
Please refer to this study by its ClinicalTrials.gov identifier: NCT02296242

Search for a list of current paroxysmal nocturnal hemoglobinuria studies actively recruiting patients. The following are a sample of the 11 studies recruiting PNH patients in the United States.

Title/Link to more information

Study Purpose

Study Coordinator

A Phase I Study to Assess the Safety APL-2 as an Add-On to Standard of Care in Subjects With PNH This study will be the initial exploration of APL-2 in patients with PNH. The assessments of the safety, tolerability, PK, and PD following administration of single and multiples doses of APL-2 will guide decisions to further develop the drug. This study is being conducted at the University of Louisville, KY
Contact: Candace Depp        pnh@apellis.com
Please refer to this study by its ClinicalTrials.gov identifier: NCT02264639

Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry

This study is a collection of data to evaluate safety and characterize progression of Paroxysmal Nocturnal Hemoglobinuria (PNH). Johns Hopkins University Medical Center , Baltimore
Contact: Lynn Sanders 203-439-9609 sandersl@alxn.com
Please refer to this study by its ClinicalTrials.gov identifier: NCT01374360